Skip to content

Delcath Systems DCTH Preferred Stock, Shares Issued

Preferred Stock, Shares Issued at other companies

Boston Scientific logo
Boston ScientificBSX
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
Exelixis logo
ExelixisEXEL

Other financials

Income statement

See full
Revenue$25.0M+26.3%
Gross profit$21.3M+25.5%
Operating income-$1.6M-355%
Net income-$1.1M-200%
EPS (diluted)-$0.03-200%

Balance sheet

See full
Cash & equivalents$41.3M+223%
Total debt$907.0K-10.7%
Total equity$112.7M+40.5%
Total assets$124.8M+43.0%

Cash flow

See full
Operating cash flow$857.0K-61.1%
CapEx$570.0K+307%
Free cash flow$287.0K-86.1%

Valuation

See full
Market cap$425.31M-11.8%
Enterprise value$384.91M-18.2%
P/E120.6×
P/S4.7×-4.3×

Profitability

See full
Gross margin86%+1.1pp
Operating margin-118.1%-56.8pp
Net margin1.5%+0.8pp
FCF margin21.2%+15.2pp

Returns & leverage

See full
Return on equity1.9%+1.0pp
Debt / equity0.0×
Current ratio11.2×-4.7×

Where this comes from

Reported directly by Delcath Systems in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesIssued.

The official record: Delcath Systems’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Delcath Systems's preferred stock, shares issued.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Delcath Systems's preferred stock, shares issued?
Delcath Systems (DCTH) reported preferred stock, shares issued of $14.19K in Q1 2026.
How has Delcath Systems's preferred stock, shares issued changed year-over-year?
Delcath Systems's preferred stock, shares issued decreased by 0.0% year-over-year, from $14.19K to $14.19K.
What is the long-term trend for Delcath Systems's preferred stock, shares issued?
Over 4 years (2021 to 2025), Delcath Systems's preferred stock, shares issued has grown at a 5.7% compound annual growth rate (CAGR), from $11.36K to $14.19K.